FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
RESEARCH TRIANGLE PARK, N.C., April 07, 2016 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the following investor conferences:
- The 15th Annual Needham Healthcare Conference in New York on Tuesday, April 12, 2016 at 10:40 a.m. Eastern Time
- The Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Wednesday, May 11, 2016 at 10:40 a.m. Pacific Time
Links to a live audio webcast and replay of these presentations may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX4161, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. In December 2014, RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, was approved by the FDA and is available to treat flu patients in the U.S. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910
